Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma.

about

Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma.

Item

http://www.wikidata.org/entity/Q38548134

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Recommendations on the clinica ...... yndromes and multiple myeloma.

@en

type

Item

label

Recommendations on the clinica ...... yndromes and multiple myeloma.

@en

prefLabel

Recommendations on the clinica ...... yndromes and multiple myeloma.

@en

P1476

Recommendations on the clinica ...... syndromes and multiple myeloma

@en

P2093

Adolfo de la Fuente

http://www.w3.org/2001/XMLSchema#string

Asunción Echeveste

http://www.w3.org/2001/XMLSchema#string

Asunción Peña

http://www.w3.org/2001/XMLSchema#string

Carlos Grande

http://www.w3.org/2001/XMLSchema#string

Elena Pérez Ceballos

http://www.w3.org/2001/XMLSchema#string

Felipe Casado

http://www.w3.org/2001/XMLSchema#string

Francisco Javier Peñalver

http://www.w3.org/2001/XMLSchema#string

Guillermo Debén

http://www.w3.org/2001/XMLSchema#string

Javier Loscertales

http://www.w3.org/2001/XMLSchema#string

Jose Luis Sastre

http://www.w3.org/2001/XMLSchema#string

P2860

Bendamustine in indolent non-Hodgkin's lymphoma: a practice guide for patient management

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.

High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).

Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.

Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.

Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.

Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.

Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study.

Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.

P304

532-540

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/EJH.12633

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Julio Delgado

Antonio Salar

Javier de la Rubia

P577

2015-08-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26179864

http://www.w3.org/2001/XMLSchema#string